PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.00
Negative OCF/share while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would examine if a turnaround is realistic.
-0.00
Negative FCF/share while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would question if the business is too capex-heavy.
No Data
No Data available this quarter, please select a different quarter.
0.82
Ratio 1.25–1.5x Drug Manufacturers - Specialty & Generic median of 0.59. Mohnish Pabrai would confirm that earnings truly convert to cash better than peers.
No Data
No Data available this quarter, please select a different quarter.